EDIT Editas Medicine Inc

Price (delayed)

$49.76

Market cap

$3.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.72

Enterprise value

$2.85B

Sector: Healthcare
Industry: Biotechnology

Highlights

Editas Medicine's gross profit has soared by 181% from the previous quarter
The revenue has soared by 181% since the previous quarter
The debt has soared by 51% YoY but it has contracted by 7% from the previous quarter

Key stats

What are the main financial stats of EDIT
Market
Shares outstanding
62.33M
Market cap
$3.1B
Enterprise value
$2.85B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.02
Price to sales (P/S)
33.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.1
Earnings
Revenue
$91.6M
EBIT
-$98.56M
EBITDA
-$95M
Free cash flow
-$106.11M
Per share
EPS
-$1.72
Free cash flow per share
-$1.71
Book value per share
$7.08
Revenue per share
$1.47
TBVPS
$9.61
Balance sheet
Total assets
$597.16M
Total liabilities
$156.01M
Debt
$26.71M
Equity
$441.15M
Working capital
$452.01M
Liquidity
Debt to equity
0.06
Current ratio
9.25
Quick ratio
9.06
Net debt/EBITDA
2.66
Margins
EBITDA margin
-103.7%
Gross margin
100%
Net margin
-99.6%
Operating margin
-118.3%
Efficiency
Return on assets
-16.4%
Return on equity
-26.7%
Return on invested capital
-46.3%
Return on capital employed
-18.2%
Return on sales
-107.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
1.26%
1 week
-11.94%
1 month
-24.33%
1 year
110.05%
YTD
-29.03%
QTD
-29.03%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$91.6M
Gross profit
$91.6M
Operating income
-$108.39M
Net income
-$91.25M
Gross margin
100%
Net margin
-99.6%
Editas Medicine's gross profit has soared by 181% from the previous quarter
The revenue has soared by 181% since the previous quarter
The net margin has soared by 88% YoY and by 75% from the previous quarter
EDIT's operating margin has surged by 87% year-on-year and by 75% since the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
7.02
P/S
33.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.1
EDIT's EPS is up by 31% since the previous quarter and by 30% year-on-year
EDIT's equity has soared by 110% year-on-year and by 3.4% since the previous quarter
EDIT's P/B is 53% above its last 4 quarters average of 4.6 and 35% above its 5-year quarterly average of 5.2
The revenue has soared by 181% since the previous quarter
The P/S is 62% less than the 5-year quarterly average of 88.5 and 27% less than the last 4 quarters average of 46.5

Efficiency

How efficient is Editas Medicine business performance
EDIT's return on sales has surged by 88% year-on-year and by 75% since the previous quarter
The ROE has soared by 53% YoY and by 43% from the previous quarter
Editas Medicine's ROA has increased by 48% YoY and by 38% from the previous quarter
EDIT's return on invested capital is up by 35% since the previous quarter and by 27% year-on-year

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
The current ratio has soared by 82% YoY and by 3.4% from the previous quarter
Editas Medicine's quick ratio has surged by 82% YoY and by 2.8% QoQ
The debt is 94% less than the equity
EDIT's equity has soared by 110% year-on-year and by 3.4% since the previous quarter
The debt has soared by 51% YoY but it has contracted by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.